Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 2, 2015, Pages 331-338

  Heimann, S M ^a   Cornely, O A ^a,b   Wisplinghoff, H ^a   Kochanek, M ^a   Stippel, D ^c   Padosch, S A ^c   Langebartels, G ^c   Reuter, H ^a   Reiner, M ^a   Vierzig, A ^c   Seifert, H ^a,b   Vehreschild, M J G T ^a,b   Glossmann, J ^a   Franke, B ^a,b   Vehreschild, J J ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b German Centre for Infection Research (DZIF)   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; ANTIFUNGAL AGENT; LIPOPEPTIDE;

ADOLESCENT; ADULT; AGED; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; ASSESSMENT OF HUMANS; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDEMIA; CHILD; DRUG CHOICE; DRUG COST; DRUG TREATMENT FAILURE; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PEDIATRIC RISK OF MORTALITY; PHYSICIAN; PRIORITY JOURNAL; SURVIVAL; ECONOMICS; INFANT; MIDDLE AGED; PRESCHOOL CHILD; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; INFANT; INTENSIVE CARE UNITS; LIPOPEPTIDES; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921816979     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2230-8     Document Type: Article

References (27)

1. Bouza E, Muñoz P (2008) Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 32(Suppl 2):S87–S91
2. Rodríguez D, Almirante B, Cuenca-Estrella M, Rodríguez-Tudela JL, Mensa J, Ayats J, Sanchez F, Pahissa A; Barcelona Candidemia Project (2010) Predictors of candidaemia caused by non-albicans Candida species: results of a population-based surveillance in Barcelona, Spain. Clin Microbiol Infect 16(11):1676–1682
3. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K; EPIC II Group of Investigators (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302(21):2323–2329
4. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ; Anidulafungin Study Group (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356(24):2472–2482
5. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45(7):883–893
6. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA; Micafungin Invasive Candidiasis Working Group (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369(9572):1519–1527
7. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM (2009) Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 48(12):1695–1703
8. Guery BP, Arendrup MC, Auzinger G, Azoulay E, Borges Sá M, Johnson EM, Müller E, Putensen C, Rotstein C, Sganga G, Venditti M, Zaragoza Crespo R, Kullberg BJ (2009) Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med 35(1):55–62
9. Xu Y, Chen L, Li C (2008) Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J Antimicrob Chemother 61(4):798–804
10. Tortorano AM, Prigitano A, Biraghi E, Viviani MA; FIMUA-ECMM Candidaemia Study Group (2005) The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production. J Antimicrob Chemother 56(4):777–779
11. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ; Mycoses Study Group (2012) Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 54(8):1110–1122
12. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ; ESCMID Fungal Infection Study Group (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19–37
13. Olaechea PM, Palomar M, León-Gil C, Alvarez-Lerma F, Jordá R, Nolla-Salas J, León-Regidor MA; EPCAN Study Group (2004) Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 23(4):323–330
14. Kett DH, Azoulay E, Echeverria PM, Vincent JL; Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators (2011) Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 39(4):665–670
15. Solberg BC, Dirksen CD, Nieman FH, van Merode G, Poeze M, Ramsay G (2008) Changes in hospital costs after introducing an intermediate care unit: a comparative observational study. Crit Care 12(3):R68
16. Jacobs P, Rapoport J, Edbrooke D (2004) Economies of scale in British intensive care units and combined intensive care/high dependency units. Intensive Care Med 30(4):660–664
17. Heimann SM, Cornely OA, Vehreschild MJ, Glossmann J, Kochanek M, Kreuzer KA, Hallek M, Vehreschild JJ (2014) Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis. Mycoses 57(2):90–97
18. Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ (1999) The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 20(11):725–730
19. Schulenburg JMGW, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schöffski O (2007) German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Gesundh Ökon Qual Manag 12:285–290
20. Institute for Quality and Efficiency in Health Care (IQWIG) (2009) Methods for health economic evaluation. Available online at: https://www.iqwig.de/en/methods/methods_papers/health_economic_evaluation.3022.html
21. Ärztekammer Nordrhein (2011) Berufsordnung für die nordrheinischen Ärztinnen und Ärzte. Available online at: http://www.aekno.de/page.asp?pageID=57. Accessed 3 March 2014
22. Gesundheitsdatenschutzgesetz (GDSG) NRW (1999) Gesetz zum Schutz personenbezogener Daten im Gesundheitswesen. Available online at: http://www.duesseldorf.de/datenschutz/rechtsgrundlagen/gdsg.pdf. Accessed 3 March 2014
23. Zilberberg MD, Kollef MH, Arnold H, Labelle A, Micek ST, Kothari S, Shorr AF (2010) Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 10:150
24. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13(10):818–829
25. Wong DT, Crofts SL, Gomez M, McGuire GP, Byrick RJ (1995) Evaluation of predictive ability of APACHE II system and hospital outcome in Canadian intensive care unit patients. Crit Care Med 23(7):1177–1183
26. Beck DH, Taylor BL, Millar B, Smith GB (1997) Prediction of outcome from intensive care: a prospective cohort study comparing Acute Physiology and Chronic Health Evaluation II and III prognostic systems in a United Kingdom intensive care unit. Crit Care Med 25(1):9–15
27. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41(9):1232–1239